TiCARos
Latest round
- Series D
Last raised
- Mar 2026
Total raised
- $43M
Investors
- 15
About TiCARos
Based in Seoul, South Korea, and founded in 2018, TiCARos specializes in developing immuno-oncology treatment by leveraging CAR-T therapy. On its establishment in 2018, the company had a research partnership with the National Cancer Center. In 2020, Prof. Sung-soo Yoon of Seoul National University Hospital was appointed as a scientific advisor and the company made a research partnership with Seoul National University Hospital, Division of Hematology & Medical Oncology. The company develops the CAR-T manufacturing process by introducing Miltenyi's CliniMACS Prodigy equipment, a closed and fully automated system from the initial development stage. This established a system that can produce reproducible and safe CAR-T therapeutics by minimizing process variables compared to manual production by researchers and preventing cross-contamination through closed system production. The company plans to allocate the March 2026 funds towards the completion of clinical trials for its blood cancer medication and the initiation of trials for its tumor treatment.
Who invested in TiCARos
15 investors across 4 rounds
See all investors in TiCARos
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about TiCARos
Who invested in TiCARos?
TiCARos has 15 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TiCARos raised?
TiCARos has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did TiCARos last raise money?
TiCARos's most recent round on record is a Series D, in Mar 2026.
What does TiCARos do?
Based in Seoul, South Korea, and founded in 2018, TiCARos specializes in developing immuno-oncology treatment by leveraging CAR-T therapy.
Where is TiCARos headquartered?
TiCARos is headquartered in Seoul, South Korea.
Which VCs invest in companies like TiCARos?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at TiCARos's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like TiCARos? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.